Connect Biopharma Receives Patent for CBP-307

▴ Connect Biopharma Receives Patent for CBP-307
Connect Biopharma Enhances its Intellectual Property Estate for CBP-307, a Targeted Therapy with Potential in Multiple Autoimmune Diseases, with Patent Issuances in the United States, EU, Japan and Australia

Connect Biopharma, a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules recently announced that, it has received patent grants from the European Patent Office (No. EP3048103B), the United State Patent and Trademark Office (No. US10280158B2) and Japan Patent Office (No. JP6470757B2), and the Australian Patent Office (No. AU2014323822B2) for CBP-307. These issuances broadly expand Connect Biopharma's intellectual property estate for CBP-307 beyond the patent issued by the China National Intellectual Property Administration (No. CN103450171B) in July 2015. The patents cover the composition of matter of the drug candidate and related compounds and have patent terms extending to no earlier than September 2033 for the patent issued in China and to September 2034 for the other patents.

CBP-307 is a proprietary small molecule and orally active S1P1 agonist currently in Phase 2 clinical development in patients with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The molecule was discovered using Connect Biopharma's validated T cell-modulating discovery platform, which radically enhances and speeds identification of best- and first-in-class immune modulators.

In addition to the above-mentioned issued patents, Connect Biopharma has patent and patent applications covering the formulation and other aspects of CBP-307 that are likely to further extend the intellectual property protection of the drug candidate.

"These patent grants provide very strong intellectual property protection for CBP-307 and related compounds in all of our major markets", said Dr. Zheng Wei, Co-founder and CEO of Connect Biopharma. "The successful global patent prosecution of composition of matter of CBP-307 and related compounds validates our innovative capacity and our ability to deliver highly differentiated therapeutics with strong worldwide intellectual property protection. We believe that CBP-307 has tremendous clinical and commercial potential in the treatment of IBD. Our robust patent estate for this molecule creates a significant barrier to competition and strongly positions us to capture a significant portion of the market for IBD therapies, which is projected to reach more than $20 billion globally by 2026 for ulcerative colitis and Crohn's disease."

CBP-307 is a novel second-generation agonist of the sphingosine-1-phosphate 1 receptor (S1P1), a G-protein coupled receptor (GPCR) that plays a central role in regulating T cell movement. Discovered using Connect's proprietary T cell modulation screening platform, CBP-307 is the most potent S1P1 agonist reported and has excellent physiochemical properties. In two completed Phase 1 randomized, double blind, placebo-controlled studies, CBP-307 exhibited an excellent safety profile and potent T cell modulation activity as well as optimal pharmacokinetic and pharmacodynamic profiles, demonstrating best-in-class potential. Two Phase 2 studies of CBP-307 are currently ongoing to evaluate its efficacy and safety in patients with moderate-to-severe ulcerative colitis and moderate-to-severe Crohn's disease.

Tags : #Connectbiopharma #Intellectualproperty #Inflammatoryboweldiseases #Cbp-307

About the Author

Team Medicircle

Related Stories

Loading Please wait...

Trending Now

China ropes in more countries for its COVID-19 vaccine trialsSeptember 29, 2020
Antarctica is still free of Covid-19. Can it stay that way?September 29, 2020
Over 200 travellers from India barred from Dubai flight over invalid Covid-19 testsSeptember 29, 2020
Netherland focuses on more stricker rule to comabt COVID-19 September 29, 2020
WHO aims to provide 120 Million rapid Coronavirus tests for poorer statesSeptember 29, 2020
UN chief on 1 Million COVID-19 deathsSeptember 29, 2020
Bahrain reports 585 Covid-19 cases, 777 recoveriesSeptember 28, 2020
Bringing hepatitis C testing and treatment to underserved communities in MadridSeptember 28, 2020
Polish doctor recovers from severe COVID-19 through rehabilitationSeptember 28, 2020
WHO supports rehabilitation of COVID-19 and other patients in UkraineSeptember 28, 2020
WHO work with migrant camps in Greece September 28, 2020
US employers being sued for COVID-19 infection spread September 28, 2020
Global Coronavirus deaths cross 1 Million markSeptember 28, 2020
Highly effective antibodies identified, may lead to passive COVID-19 vaccineSeptember 26, 2020
Europe has a lot of work to do to prevent COVID-19 transmission :WHOSeptember 26, 2020
Two million Coronavirus deaths : WHO September 26, 2020
Johnson & Johnson COVID-19 vaccine produces strong results September 26, 2020
New York to permanently switch to outdoor dining amid pandemicSeptember 26, 2020
WHO gave blessing for Coronavirus vaccine emergency use programme: ChinaSeptember 26, 2020
US surpasses 7 Million Coronavirus casesSeptember 26, 2020